MARKET

ZSAN

ZSAN

Zosano Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5340
+0.0089
+1.69%
Closed 16:00 12/06 EST
OPEN
0.5200
PREV CLOSE
0.5251
HIGH
0.5479
LOW
0.5010
VOLUME
1.12M
TURNOVER
--
52 WEEK HIGH
3.060
52 WEEK LOW
0.5010
MARKET CAP
63.20M
P/E (TTM)
-1.8510
1D
5D
1M
3M
1Y
5Y
BRIEF-Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
reuters.com · 6d ago
'Zosano: From Phase 3 To Approval Of A Best-In-Class Migraine Treatment' -Seeking Alpha Blog Post From Contributor
https://seekingalpha.com/article/4265747-zosano-phase-3-approval-best-class-migraine-treatment
Benzinga · 11/19 21:43
Aiming to make Covid vaccines easier to take, East Bay company pushes forward with microneedle patch
With the pandemic claiming more than 5 million lives globally and vaccine uptake slow in some regions, several companies are looking for new ways to get Covid-treating drugs or vaccines to aptients more easily.
American City Business Journals · 11/17 22:49
Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Nov. 17, 2021: TDOC, VRAR, ZSAN, RDW, SNDL
Today's 5 Stock Ideas: Teladoc (TDOC) - The company will host an investor day event on Thursday. The event will begin at 10 a.m. EST. Investor day events can often contain news catalysts and can lead to added
Benzinga · 11/17 14:14
Zosano formulates COVID-19 vaccine candidate using patch technology
Zosano Pharma (NASDAQ:ZSAN) has gained ~12.5% in the pre-market after the company announced the successful formulation of a COVID-19 vaccine candidate using its microneedle patch system. Zosano’s patch, consisting of a range of
Seekingalpha · 11/17 13:27
BRIEF-Zosano Pharma Announces The Successful Formulation Of A Covid-19 Vaccine Candidate On Its Microneedle Patch System
reuters.com · 11/17 13:02
Zosano Pharma Announces the Successful Formulation of a COVID-19 Vaccine Candidate on its Microneedle Patch System
FREMONT, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the successful formulation of a COVID-19 vaccine candidate, obtained from a vaccine developer, utilizing...
GlobeNewswire · 11/17 13:00
Zosano Pharma Corporation (ZSAN) Reports Q3 Loss, Misses Revenue Estimates
Zacks.com · 11/10 23:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZSAN. Analyze the recent business situations of Zosano Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ZSAN stock price target is 2.000 with a high estimate of 2.000 and a low estimate of 2.000.
High2.000
Average2.000
Low2.000
Current 0.5340
EPS
Actual
Estimate
-0.08-0.06-0.04-0.02
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 45
Institutional Holdings: 13.02M
% Owned: 11.00%
Shares Outstanding: 118.35M
TypeInstitutionsShares
Increased
10
355.52K
New
2
151.82K
Decreased
7
1.68M
Sold Out
6
67.52K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.95%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
President/Chief Executive Officer/Director
Steven Lo
Chief Financial Officer
Christine Matthews
Vice President
Donald Kellerman
Lead Director/Independent Director
Kenneth Greathouse
Director
Kathy McGee
Independent Director
Steven Elms
Independent Director
Linda Grais
Independent Director
Joseph Hagan
Independent Director
Kleanthis Xanthopoulos
No Data
About ZSAN
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The Company is focused on providing systemic administration of therapeutics to patients using its ransdermal microneedle system (the System). The System is designed to facilitate drug absorption into the bloodstream. The Company’s lead product candidate is Qtrypta (M207). Qtrypta is a formulation of zolmitriptan delivered utilizing its System. Zolmitriptan is a serotonin receptor agonists known as triptans and is used as an acute treatment for migraine. Qtrypta is designed for absorption of zolmitriptan into the bloodstream without dependence on the gastrointestinal (GI) tract. Its same formulation, development name C213, is the treatment to provide relief for cluster headache.

Webull offers kinds of Zosano Pharma Corp stock information, including NASDAQ:ZSAN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZSAN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZSAN stock methods without spending real money on the virtual paper trading platform.